Search Back New search Go to resultsDiseaseMain groupCross-Sectional, Transplantation, Cellular TherapySolid TumorsProtocol groupGynecological OncologyVisceral SurgeryDiseasePeritoneal MesotheliomaSubgroupICD10C45.1MeSHMesothelioma, CysticSequenceChemotherapyChemo-substanceAtezolizumabBevacizumabChemo-substanceAtezolizumabBevacizumabChemo-substanceAtezolizumabBevacizumabChemo-substanceAtezolizumabBevacizumabNo. Substances2 RadiotherapySupportive therapySupportive substanceBalanced Crystalloid SolutionSupportive substanceBalanced Crystalloid SolutionSupportive substanceBalanced Crystalloid SolutionSupportive substanceBalanced Crystalloid SolutionNo. Substances1Protocol classificationTherapy classificationalternativeIntensityStandard doseTherapy indicationSecond lineTherapy phaseTherapy intentionpalliativeRisksAnemia Hb below 8g/dlArthalgiaAstheniaConstipationDiarrheaEmetogenicity (MASCC/ESMO)HypertensionIncrease AminotransferasesLymphopeniaPainPancreatitisProteinuriaPruritusThrombocytopenia below 50 000/µlThromboembolic Event only studiesPublicationAuthorRaghav KDiseasePeritonealmesotheliom, Zweitlinie oder höher, ECOG 0-1OriginThe University of Texas MD Anderson Cancer Center, Houston, TexasProtocols in Revision 1 protocol foundProtocols under revision.Atezolizumab 1200 / Bevacizumab 15, peritoneal mesothelioma (PID1934 V1.0)
